Mind the Magnesium, in Dantrolene Suppression of Malignant Hyperthermia

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2017 Apr 27

PMID 28442565

Citations 3

Authors

Stephen C Cannon

Affiliations

Soon will be listed here.

Citing Articles

Ryanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches.

Lawal T, Todd J, Meilleur K Neurotherapeutics. 2018; 15(4):885-899.

PMID: 30406384 PMC: 6277304. DOI: 10.1007/s13311-018-00677-1.

Junctional membrane Ca dynamics in human muscle fibers are altered by malignant hyperthermia causative RyR mutation.

Cully T, Choi R, Bjorksten A, Stephenson D, Murphy R, Launikonis B Proc Natl Acad Sci U S A. 2018; 115(32):8215-8220.

PMID: 30038012 PMC: 6094124. DOI: 10.1073/pnas.1800490115.

Dantrolene : From Malignant Hyperthermia to Alzheimer's Disease.

Shi Y, Wang Y, Wei H CNS Neurol Disord Drug Targets. 2018; 18(9):668-676.

PMID: 29921212 PMC: 7754833. DOI: 10.2174/1871527317666180619162649.

References

Diaz-Sylvester P, Porta M, Copello J . Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP. Am J Physiol Cell Physiol. 2008; 294(4):C1103-12. PMC: 2465464. DOI: 10.1152/ajpcell.90642.2007. View

Westerblad H, Allen D . Myoplasmic free Mg2+ concentration during repetitive stimulation of single fibres from mouse skeletal muscle. J Physiol. 1992; 453:413-34. PMC: 1175565. DOI: 10.1113/jphysiol.1992.sp019236. View

Harrison G . Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 1975; 47(1):62-5. DOI: 10.1093/bja/47.1.62. View

Monnier N, Procaccio V, STIEGLITZ P, Lunardi J . Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997; 60(6):1316-25. PMC: 1716149. DOI: 10.1086/515454. View

Ellis K, BRYANT S . Excitation-contraction uncoupling in skeletal muscle by dantrolene sodium. Naunyn Schmiedebergs Arch Pharmacol. 1972; 274(1):107-9. DOI: 10.1007/BF00501011. View

Laver D, Owen V, Junankar P, Taske N, Dulhunty A, Lamb G . Reduced inhibitory effect of Mg2+ on ryanodine receptor-Ca2+ release channels in malignant hyperthermia. Biophys J. 1997; 73(4):1913-24. PMC: 1181092. DOI: 10.1016/S0006-3495(97)78222-5. View

Denborough M, FORSTER J, LOVELL R, Maplestone P, VILLIERS J . Anaesthetic deaths in a family. Br J Anaesth. 1962; 34:395-6. DOI: 10.1093/bja/34.6.395. View

Steele D, Duke A . Defective Mg2+ regulation of RyR1 as a causal factor in malignant hyperthermia. Arch Biochem Biophys. 2006; 458(1):57-64. DOI: 10.1016/j.abb.2006.03.001. View

Nelson T, Lin M, Zapata-Sudo G, Sudo R . Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications. Anesthesiology. 1996; 84(6):1368-79. DOI: 10.1097/00000542-199606000-00013. View

10.

Ellis K, Carpenter J . Mechanism of control of skeletal-muscle contraction by dantrolene sodium. Arch Phys Med Rehabil. 1974; 55(8):362-9. View

11.

Fruen B, Mickelson J, Louis C . Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem. 1997; 272(43):26965-71. DOI: 10.1074/jbc.272.43.26965. View

12.

Szentesi P, Collet C, Sarkozi S, Szegedi C, Jona I, Jacquemond V . Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. J Gen Physiol. 2001; 118(4):355-75. PMC: 2233700. DOI: 10.1085/jgp.118.4.355. View

13.

Choi R, Koenig X, Launikonis B . Dantrolene requires Mg to arrest malignant hyperthermia. Proc Natl Acad Sci U S A. 2017; 114(18):4811-4815. PMC: 5422773. DOI: 10.1073/pnas.1619835114. View

14.

Gillard E, Otsu K, Fujii J, Khanna V, De Leon S, Derdemezi J . A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 1991; 11(3):751-5. DOI: 10.1016/0888-7543(91)90084-r. View

15.

Palnitkar S, Jimenez L, Morimoto H, Parness J . The skeletal muscle ryanodine receptor identified as a molecular target of [3H]azidodantrolene by photoaffinity labeling. Biochemistry. 2001; 40(2):531-42. DOI: 10.1021/bi001502s. View

16.

KOLB M, Horne M, Martz R . Dantrolene in human malignant hyperthermia. Anesthesiology. 1982; 56(4):254-62. DOI: 10.1097/00000542-198204000-00005. View

17.

Paul-Pletzer K, Yamamoto T, Bhat M, Ma J, Ikemoto N, Jimenez L . Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002; 277(38):34918-23. DOI: 10.1074/jbc.M205487200. View

18.

Lamb G, Stephenson D . Effects of intracellular pH and [Mg2+] on excitation-contraction coupling in skeletal muscle fibres of the rat. J Physiol. 1994; 478 ( Pt 2):331-9. PMC: 1155689. DOI: 10.1113/jphysiol.1994.sp020253. View

19.

Loke J, Maclennan D . Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. Am J Med. 1998; 104(5):470-86. DOI: 10.1016/s0002-9343(98)00108-9. View

20.

Wagner 2nd L, Groom L, Dirksen R, Yule D . Characterization of ryanodine receptor type 1 single channel activity using "on-nucleus" patch clamp. Cell Calcium. 2014; 56(2):96-107. PMC: 4120733. DOI: 10.1016/j.ceca.2014.05.004. View